Cargando…

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation

Preclinical studies have demonstrated that the chemotherapeutic action of oxaliplatin, a third generation platinum derivative, is improved when combined with cetuximab, a monoclonal antibody inhibitor of epidermal growth factor receptors. To explore the mechanism of this synergistic benefit, we used...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balin-Gauthier, D, Delord, J-P, Pillaire, M-J, Rochaix, P, Hoffman, J-S, Bugat, R, Cazaux, C, Canal, P, Allal, B C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359709/ https://www.ncbi.nlm.nih.gov/pubmed/18182978 http://dx.doi.org/10.1038/sj.bjc.6604134

Ejemplares similares

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model
por: Delord, J-P, et al.
Publicado: (2010)

Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells
por: Temmink, O H, et al.
Publicado: (2007)

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
por: Jonker, D J, et al.
Publicado: (2014)

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer
por: Marzi, L, et al.
Publicado: (2016)

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil
por: Chen, C-C, et al.
Publicado: (2007)

Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
por: Meira, D D, et al.
Publicado: (2009)

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
por: Roberts, D L, et al.
Publicado: (2009)

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients
por: Pieck, A C, et al.
Publicado: (2008)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
por: Lesterhuis, W J, et al.
Publicado: (2010)

Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
por: Baro, M, et al.
Publicado: (2014)

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
por: Lee, J-L, et al.
Publicado: (2014)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
por: Znojek, P, et al.
Publicado: (2014)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
por: Montagut, C, et al.
Publicado: (2010)

Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells
por: Valenzuela, M, et al.
Publicado: (2014)

Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells
por: Liu, P, et al.
Publicado: (2012)

Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy
por: Golding, J P, et al.
Publicado: (2013)

Comparative analysis of xanafide cytotoxicity in breast cancer cell lines
por: Alami, N, et al.
Publicado: (2007)

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes
por: Feder-Mengus, C, et al.
Publicado: (2007)

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
por: Lévi, Francis, et al.
Publicado: (2017)

Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines
por: Vilar, E, et al.
Publicado: (2008)

Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy
por: Papaevangelou, E, et al.
Publicado: (2015)

Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma
por: Gottlieb, D J, et al.
Publicado: (2006)

The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines
por: Kostrzewa-Nowak, D, et al.
Publicado: (2005)

A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia
por: Gallagher, W M, et al.
Publicado: (2005)

Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration
por: Lee, C M, et al.
Publicado: (2006)

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
por: Goto, T, et al.
Publicado: (2008)

Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound
por: Paliwal, S, et al.
Publicado: (2005)

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells
por: Benhadji, K A, et al.
Publicado: (2008)

Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells
por: Singh, R K, et al.
Publicado: (2008)

Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells
por: Thiel, U, et al.
Publicado: (2011)

Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide
por: Conway, Gillian E, et al.
Publicado: (2016)

MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea
por: McDaid, J R, et al.
Publicado: (2009)

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer
por: Horlock, C, et al.
Publicado: (2009)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
por: Boni, J P, et al.
Publicado: (2008)

Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPO
por: Rebuffat, S A, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_kthev964n0m2nf2q6o1dtqpern